Why Grail Stock Zoomed Nearly 7% Higher on Monday

On a generally gloomy Monday for the stock market, specialty healthcare diagnostics company Grail (NASDAQ: GRAL) was a bright light. Following two analyst price target raises, investors piled into the company's shares, driving them almost 7% higher in value. Both hikes were substantial, but the prize belonged to Morgan Stanley's Tejas Savant. He more than doubled his Grail price target, lifting it to $85 per share from his preceding level of $38. Although that change was significant, Savant left his equalweight (read: hold) recommendation intact. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool